Physician profile
Duaa Ali
NPI 1043941313
$2,037.91
in general payments reported to CMS, 2019-2025
15 companies · $868 in 2025
The $868 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $261 · 2024: $909 · 2025: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,037.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $415.54 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $390.44 | 2024-2025 | Repatha, Evenity, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $208.46 | 2023-2024 | |
| Lilly USA, LLC | $207.46 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $172.02 | 2023-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $125.00 | 2024 | |
| Glaxosmithkline, LLC. | $93.01 | 2024 | Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.61 | 2024-2025 | Jardiance |
| Pfizer INC. | $77.12 | 2023-2025 | |
| Cipher Pharmaceuticals US LLC | $76.03 | 2025 | Spinosad, Natroba |
| Merck Sharp & Dohme LLC | $54.15 | 2023-2024 | Vaxelis, Gardasil 9, Vaxneuvance |
| Exact Sciences Corporation | $46.48 | 2023-2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $38.79 | 2023-2024 | |
| Phadia US INC. | $24.33 | 2024 | Immunocap |
| Cranial Technologies, INC | $21.47 | 2023 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duaa Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.